| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
|
|
|
|||||||
|
|||||||||
Clinical Studies |
Institut National de la Sante et de la Recherche Medicale, Unite 369, Faculte de Medecine Lyon-RTH Laennec, France.
Serum thyroglobulin (Tg) concentration increases in diverse thyroid pathophysiological situations. We examined whether Tg molecules appearing in the serum of patients with Graves' disease (GD), subacute thyroiditis (ST) or differentiated thyroid cancer (DTC) have distinctive biochemical properties. We used ultracentrifugation on sucrose gradient and Western blot to analyze structural parameters of immunoreactive Tg in complete serum from 40 patients with GD, ST or DTC. Purified human Tg was used as reference. Immunoreactive Tg from ST or DTC sera sedimented in a single, rather symmetrical peak as purified 19S Tg. In GD sera without detectable anti-Tg autoantibodies (TgaAb), about 80% of immunoreactive Tg was recovered in a Tg dimer peak that often split into two components; the remaining Tg immunoreactivity (10-30%) sedimented faster and was polydispersed. In GD sera containing TgaAb, immunoreactive Tg was recovered in a peak sedimenting faster than 19S Tg corresponding to immune complexes identified by protein A adsorption. Using a Western blot procedure, optimized to detect 0.1 ng Tg in serum. a single band of Tg, migrating as the intact Tg subunit, was always found in non-reducing conditions; the intensity of the band correlated with the immunoassayable Tg concentration. In reducing conditions, the Tg band obtained with GD or ST sera was decreased by up to 70% compared with that of purified Tg or serum Tg from patients with DTC. In conclusion, serum Tg from DTC is remarkably homogeneous and in the form of dimers dissociable into uncleaved monomers. In contrast, serum Tg from GD or ST is heterogeneous with respect to its sedimentation properties and/or the structural integrity of its polypeptide chains. These data provide information on the processes whereby Tg is released into the circulation.
This article has been cited by other articles:
|
|
 |
|
  F. Latrofa, D. Ricci, L. Grasso, P. Vitti, L. Masserini, F. Basolo, C. Ugolini, G. Mascia, A. Lucacchini, and A. Pinchera Characterization of Thyroglobulin Epitopes in Patients with Autoimmune and Non-Autoimmune Thyroid Diseases Using Recombinant Human Monoclonal Thyroglobulin Autoantibodies J. Clin. Endocrinol. Metab., February 1, 2008; 93(2): 591 - 596. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Marino and R. T. McCluskey Role of thyroglobulin endocytic pathways in the control of thyroid hormone release Am J Physiol Cell Physiol, November 1, 2000; 279(5): C1295 - C1306. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
M. Marinò, L. Chiovato, N. Mitsiades, F. Latrofa, D. Andrews, S. Tseleni-Balafouta, A. B. Collins, A. Pinchera, and R. T. McCluskey Circulating Thyroglobulin Transcytosed by Thyroid Cells Is Complexed with Secretory Components of Its Endocytic Receptor Megalin J. Clin. Endocrinol. Metab., September 1, 2000; 85(9): 3458 - 3467. [Abstract] [Full Text]
|
|
|
|
 |
|
 M. Marino, G. Zheng, L. Chiovato, A. Pinchera, D. Brown, D. Andrews, and R. T. McCluskey Role of Megalin (gp330) in Transcytosis of Thyroglobulin by Thyroid Cells. A NOVEL FUNCTION IN THE CONTROL OF THYROID HORMONE RELEASE J. Biol. Chem., March 15, 2000; 275(10): 7125 - 7137. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
